title: Management of CMV infection and disease in transplant patients. 27-29 February 2004.
abstract: The International Herpes Management Forum (IHMF) has published guidelines for the diagnosis and management of cytomegalovirus (CMV) infection and disease in solid organ (SOT) and haematopoietic stem cell transplant (HSCT) recipients. These recommendations have been updated to include, among others: (1) use of whole blood for the polymerase chain reaction (PCR) diagnosis of CMV infection; (2) CMV load measurements for prognostication and for monitoring response to anti-CMV therapy; (3) valganciclovir prophylaxis in CMV donor-positive/recipientnegative (D+/R-) SOT patients for prevention of CMV disease; (4) oral ganciclovir prophylaxis, in preference to aciclovir, to reduce incidence of CMV disease in SOT patients; (5) pre-emptive therapy with oral ganciclovir to reduce incidence of CMV disease and viraemia in liver transplant patients; (6) valaciclovir prophylaxis, in preference to high-dose oral aciclovir, to prevent CMV infection in allogeneic HSCT patients; and (7) foscarnet as an alternative to intravenous ganciclovir for pre-emptive treatment of CMV infection in allogeneic HSCT patients. New developments in the field requiring further research were highlighted, including: optimal frequency of CMV monitoring in CMV D+/R- SOT patients; optimal duration of prophylaxis for the prevention of late CMV disease; need for an acceptable viral threshold for initiation of pre-emptive therapy; and assessment of the clinical efficacy of valganciclovir for the treatment of CMV disease and as pre-emptive therapy in SOT and HSCT patients. This article presents supporting evidence for these recommendations and statements.
authors.affiliation: Division of Infectious Diseases and Internal Medicine at the Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. Razonable.Raymund@mayo.edu
authors.forename: Raymund R
authors.initials: RR
authors.lastname: Razonable
authors.forename: Vincent C
authors.initials: VC
authors.lastname: Emery
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D014180:Transplantation / Q000009:adverse effects*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents